Clinical Trial Update: Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating roflumilast as an adjunct to antidepressants for major depressive disorder, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: Tanta University | Conditions: Depressive Disorder, Major | Phase 3 | Status: RECRUITING